Pharmaceuticals

Binhai sets ambitious biomedical goals with support of key companies

TIANJIN, China, Sept. 30, 2021 /PRNewswire/ -- A news report by chinadaily.com.cn: The Binhai New Area in North China's port city of Tianjin has gathered together more than 1,500 biomedical companies that have made great scientific achievements in key areas, such as recombinant proteins and stem...

2021-10-01 01:08 1910

Penn mRNA Biology Pioneer Drew Weissman Joins RVAC's Science Advisory Board

SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- RVAC Medicines  Pte. Ltd. ("RVAC"), an emerging messager RNA (mRNA) platform company inSingapore aspiring to address various diseases with unmet medical needs for emerging markets through novel vaccines and therapeutics, today announced that one of the to...

2021-10-01 00:50 2415

Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US Clinical trials

SYDNEY, Sept. 30, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and Evergreen Theragnostics, Inc. ("Evergreen"), a radiopharmaceutical...

2021-09-30 20:03 1870

I-Mab Reports Multiple Positive Clinical Updates of Differentiated CD47 Antibody Lemzoparlimab

* The preliminary efficacy and safety data from the phase 2 U.S. trial in NHL has been submitted for presentation at ASH 2021The current U.S. NHL clinical trial has now expanded to include clinical sites inChina as an international multi-center clinical trial, which will potentially lead to a r...

2021-09-30 20:00 6689

Zantrene® kills melanoma cancer cells that overproduce FTO

* Zantrene® at low concentrations kills high FTO producing melanoma cancer cells * Sensitivity to Zantrene® correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells * Results are highly supportive of future clinical trials in ...

2021-09-30 11:58 11007

Innovent Announces the First Patient Dosed in the Phase I/II Study of IBI351 (KRAS G12C inhibitor) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, Sept. 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-09-30 08:00 4004

ObvioHealth Partners with Anatara Lifesciences to Launch First-of-its-kind Decentralized Clinical Trial in Australia

NEW YORK, Sept. 30, 2021 /PRNewswire/ -- ObvioHealth, a global Virtual Research Organization (VRO), today announces the launch of a first-of-its kind clinical trial inAustralia, using a combination of in-home data collection methods that will reduce, and in some cases, eliminate the need for fo...

2021-09-30 07:00 1645

Nanoform receives funding to solve challenges for global health

HELSINKI, Sept. 29, 2021 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies will be funded by the Bill & Melinda Gates Foundation to assess the added value Nanoform's award-winning CESS® nanoparticle engineering technology can d...

2021-09-29 21:15 2095

Everest Medicines Initiates Submission of New Drug Application in Hong Kong for XeravaTM for the Treatment of Complicated Intra-abdominal Infections

SHANGHAI, Sept. 29, 2021 /PRNewswire/ -- Everest Medicines Limited (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet ...

2021-09-29 17:44 3913

Zhaoke Ophthalmology's IND Application for Potential First Myopia Drug to Market in China and Globally, NVK-002, Approved for Phase III Clinical Trial by the CDE

* Targets broadest patient group – three to 17 years old * Two concurrent clinical trials, one leveraging global study to accelerate time to market * Phase III clinical trials testing two different doses to tailor for individual patients HONG KONG, Sept. 29, 2021 /PRNewswire/ -- Zhaoke Opht...

2021-09-29 12:17 5647

MetaCell launches innovative Cloud Hosting for life science and healthcare

CAMBRIDGE, Mass., Sept. 29, 2021 /PRNewswire/ -- MetaCell, an innovative life science software company specialized in creating cutting-edge research software for major pharma, biotech, and academic institutions, has launchedMetaCell Cloud Hosting

2021-09-29 07:54 2572

EW Nutrition launches Pretect D to support poultry gut health during challenging periods

VISBEK, Germany, Sept. 29, 2021 /PRNewswire/ -- EW Nutrition announces the launch of a novel gut health solution for poultry. Pretect D, a proprietary blend of phytomolecules, helps maintain bird performance and farm profitability. Trials indicate that Pretect D offers natural support even during...

2021-09-29 07:40 1459

I-Mab Announces Acceptance of IND Application from China NMPA for Phase 2 Clinical Trial of Enoblituzumab in Combination with Pembrolizumab in Solid Tumors

SHANGHAI and GAITHERSBURG, Md., Sept. 28, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of China Nati...

2021-09-28 20:00 4614

Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy

DURHAM, N.C. and BEIJING, Sept. 28, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public heal...

2021-09-28 08:00 5640

Bo'ao Winhealth Rare Disease Medical Center and Ali Health Jointly Launched the "Global Drug Information Platform for Rare Diseases"

BEJING, Sept. 27, 2021 /PRNewswire/ -- On September 25, 2021 in Beijing, China, the "Global Drug Information Platform for Rare Diseases" was successfully kicked off at Ali Center inBeijing. Jointly built by Bo'ao Winhealth Rare Disease Medical Center and Ali Health, the Platform aims at addressin...

2021-09-27 21:00 3792

Immunoforge Inc. receives U.S. FDA ODD for Treatment of Polymyositis

SEOUL, South Korea, Sept. 27, 2021 /PRNewswire/ -- Immunoforge (Co-CEOs Sung-min Ahn,Kiho Chang), a company specializing in developing new drugs for rare musculoskeletal diseases, has reported that their new drug candidate PF1801 has received Orphan Drug Designation (ODD) from the U.S. FDA for th...

2021-09-27 21:00 1805

Senhwa Announces Acceptance of Early Positive COVID-19 Phase II Study Abstract for Presentation at the ISIRV-WHO Conference

* Early Positive Phase 2 efficacy and safety data are both statistically significant and clinically meaningful. * No SAE related to Silmitasertib was reported. * Silmitasertib is a host-directed antiviral and an anti-inflammatory investigational therapy expected to be effective against eme...

2021-09-27 19:20 3183

Seegene Unveils Fully Automated Molecular Testing System at the 2021 AACC

* Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in theAtlanta, GA, United States * AIOS is the MDx system that integrates Seegene's liquid handler and real-time PCR instruments. * Seegene MDx system will efficiently access a wide ...

2021-09-27 19:02 3108

Lipidor announces approval to start Phase III clinical study of drug candidate AKP02 for treatment of psoriasis

STOCKHOLM, Sept. 27, 2021 /PRNewswire/ -- Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announced today that the company's Phase III clinical study of its drug candidate AKP02 for the treatment of psoriasis has been approved by the Indian Medical Products Agency and is ready to start...

2021-09-27 17:37 1904

Innovent and AnHeart Announce Interim Data from Phase 2 Trial of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, Sept. 27, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major disea...

2021-09-27 08:00 4244
1 ... 307308309310311312313 ... 339